International Red Cross and Red Crescent Movement & Gilead Sciences

International Red Cross and Red Crescent Movement: The International Red Cross and Red Crescent Movement is actively involved in the Ebola response, but its volunteers face threats and have suffered casualties, indicating significant operational challenges and risks.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

International Red Cross and Red Crescent Movement: The International Red Cross and Red Crescent Movement warned that Ebola can escalate quickly under current conditions in the Democratic Republic of the Congo.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

International Red Cross and Red Crescent Movement: The International Red Cross and Red Crescent Movement is involved in managing safe burials for Ebola victims, facing resistance from communities, and has reported the deaths of three volunteers from the outbreak.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

International Red Cross and Red Crescent Movement: Assists with safe burials; faces community resistance.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.